Article
Oncology
Gary Schwartz, Kevin Shee, Bianca Romo, Jonathan Marotti, Alexei Kisselev, Lionel Lewis, Todd Miller
Summary: A single-center phase Ib study showed that the combination of fulvestrant and the proteasome inhibitor ixazomib has a favorable safety profile and antitumor activity in patients with fulvestrant-resistant advanced ER+ breast cancer, warranting further testing.
Article
Oncology
You-Zhe Lin, Chuan-Chun Lee, Der-Yang Cho, Yuan-Liang Wang, Chia-Yun Chen, Ching-Yu Weng, Shao-Chih Chiu, Mien-Chie Hung, Shao-Chun Wang
Summary: Resistance to fulvestrant in breast cancer cells is associated with increased expression of innate immune response genes, including the NK cell ligand B7-H6. A NK-based molecular approach targeting B7-H6 with a chimeric antigen receptor (CAR) system can effectively induce cell death in resistant cancer cells, offering a new avenue to eradicate hormone-refractory malignant solid tumors.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Yu Jin Kim, Se-Kyeong Jang, Sung-Eun Hong, Chan Sub Park, Min-Ki Seong, Hyun-Ah Kim, Ki Soo Park, Chun-Ho Kim, In-Chul Park, Hyeon-Ok Jin
Summary: Targeting the YAP/TAZ-PSAT1 axis can sensitize tamoxifen-resistant MCF7 breast cancer cells by modulating the mTORC1-survivin axis.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2022)
Article
Oncology
G. R. Hancock, K. S. Young, D. J. Hosfield, C. Joiner, E. A. Sullivan, Y. Yildiz, M. Laine, G. L. Greene, S. W. Fanning
Summary: This study identified chemically unconventional antagonists of estrogen receptor alpha (ERα) that have moderate effects on the transcriptional activities of breast cancer cells, exhibit anti-proliferative properties, and engage transcriptional pathways similar to selective estrogen receptor degraders.
Article
Pharmacology & Pharmacy
Huan Tang, Zheng Zhang, Ming Zhu, Yizhuo Xie, Zhe Lv, Rui Liu, Yujia Shen, Jin Pei
Summary: The study developed estrone-modified GEM-loaded PEGylated liposomes (ES-SSL-GEM) to improve the targeting ability and therapeutic effect for lung cancer treatment. The results showed that ES-SSL-GEM had a uniform particle size, good stability, and slow release behavior. It significantly inhibited A549 cell proliferation and suppressed tumor growth, indicating its potential application in lung cancer treatment.
Article
Plant Sciences
Hongni Zhu, Jeishu You, Yi Wen, Lei Jia, Fei Gao, Kumar Ganesan, Jianping Chen
Summary: The study revealed that Angelica sinensis promotes the proliferation of ER-positive breast cancer cells and induces cancer stem cell activity, suggesting that its usage is not recommended for breast cancer treatment in terms of safety measures.
JOURNAL OF ETHNOPHARMACOLOGY
(2021)
Article
Oncology
Kenichi Watanabe, Naoki Niikura, Yuichiro Kikawa, Mari Oba, Kokoro Kobayashi, Hiroshi Tada, Shinji Ozaki, Uhi Toh, Yutaka Yamamoto, Michiko Tsuneizumi, Toshitaka Okuno, Nobutaka Iwakuma, Takashi Takeshita, Takayuki Iwamoto, Hiroshi Ishiguro, Norikazu Masuda, Shigehira Saji
Summary: The combination of fulvestrant and palbociclib is a potentially safe and effective treatment option for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Biochemistry & Molecular Biology
Guoxun Li, Jian Li, Wenqian Wang, Xiaoqing Feng, Xingkang Yu, Shuo Yuan, Wei Zhang, Jialing Chen, Caijuan Hu
Summary: Pterostilbene has anti-breast cancer activity and analog 2L, with a nitrogen heterocyclic ring in the side chain, showed the strongest inhibitory effect on MDA-MB-231 and MCF-7 cells. It induced apoptosis and inhibited tumor growth in mice without toxicity, making it a promising anti-BC lead compound.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Immunology
Ravindra Jagannath Waghole, Ashwini Vivek Misar, Neha Shashikant Kulkarni, Feroz Khan, Dattatraya Gopal Naik, Sachin Hanmant Jadhav
Summary: The present study further explored the anti-inflammatory activity and antioxidative effects of T. sulcatum and found that it significantly reduced inflammation-induced oxidative damage and the expression of pro-inflammatory cytokines. This suggests that T. sulcatum may be a potential alternative anti-inflammatory medication.
INFLAMMOPHARMACOLOGY
(2022)
Article
Multidisciplinary Sciences
Yusha'u Shu'aibu Baraya, Chee Lee Wee, Zulkarnain Mustapha, Kah Keng Wong, Nik Soriani Yaacob
Summary: The study found that F3 could stimulate anti-tumorigenic immunogenicity, increase infiltration of T cells in breast cancer, and reduce the number of tumor-associated macrophages.
Article
Biochemistry & Molecular Biology
Venugopal R. Bovilla, Mahadevaswamy G. Kuruburu, Vidya G. Bettada, Jayashree Krishnamurthy, Olga A. Sukocheva, Rajesh K. Thimmulappa, Nanjunda Swamy Shivananju, Janardhan P. Balakrishna, SubbaRao Madhunapantula
Summary: The study investigated the expression of Nrf2 in breast cancer tissues and cell lines, finding that silencing or inhibiting Nrf2 could reduce cancer cell proliferation and migration, induce cell cycle arrest and activate apoptosis, as well as sensitize breast cancer cells to cisplatin. Additionally, experimental mouse models showed that pharmacological Nrf2 inhibitor brusatol slowed tumor growth and activated anti-cancer effects in the tumor microenvironment. Further testing is needed to confirm the potential of Nrf2 as a marker and therapeutic target for chemo sensitization in drug resistant and advanced tumors.
Article
Oncology
Bora Lim, David A. Potter, Mohamad A. Salkeni, Paula Silverman, Tufia C. Haddad, Frederic Forget, Ahmad Awada, Jean-Luc Canon, Michael Danso, Alain Lortholary, Hugues Bourgeois, Elizabeth Tan-Chiu, Sylvie Vincent, Brittany Bahamon, Kevin J. Galinsky, Chirag Patel, Rachel Neuwirth, E. Jane Leonard, Jennifer R. Diamond
Summary: The study evaluated the efficacy and safety of sapanisertib plus exemestane or fulvestrant in treating advanced/metastatic hormone receptor-positive breast cancer, showing certain clinical benefit for patients. The treatment demonstrated different efficacy in patients previously sensitive or resistant to exemestane.
CLINICAL CANCER RESEARCH
(2021)
Article
Pharmacology & Pharmacy
Shanshan Chen, Jianping Jiang, Guanqun Chao, Xiaojie Hong, Haijun Cao, Shuo Zhang
Summary: This study demonstrated the potential of PTFC in protecting intestinal barrier integrity by promoting autophagy, indicating its promising role as a therapeutic candidate for NSAID-induced small intestine injury.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Chemistry, Physical
Aleksandr Kakinen, Ibrahim Javed, Thomas P. Davis, Pu Chun Ke
Summary: Amyloid diseases are global epidemics with limited solutions for diagnosis, treatment, and prevention;
The research on amyloidosis inhibition has evolved into a new frontier in nanomedicine, offering interdisciplinary research opportunities in materials, chemistry, and biophysics;
Due to the complex and overlapping physiopathologies of amyloid diseases, there is a crucial need for appropriate in vitro and in vivo models to validate novel anti-amyloidosis nanomedicines, and the development of new animal models reflecting the behavioral, symptomatic, and cross-talk hallmarks of amyloid diseases such as Alzheimer's, Parkinson's, and type 2 diabetes.
NANOSCALE HORIZONS
(2021)
Article
Biochemistry & Molecular Biology
Aggeliki K. Meligova, Dimitra Siakouli, Sotiria Stasinopoulou, Despoina S. Xenopoulou, Maria Zoumpouli, Vassiliki Ganou, Eleni-Fani Gkotsi, Aristotelis Chatziioannou, Olga Papadodima, Eleftherios Pilalis, Michael N. Alexis, Dimitra J. Mitsiou
Summary: Adjuvant endocrine therapy (AET) is the preferred treatment for early-stage estrogen receptor alpha (ER alpha)-positive breast cancer (BC). However, around 40% of tamoxifen-treated patients do not respond well to AET, necessitating the development of new treatment options and reliable predictors of therapeutic response. This study investigated the role of ER beta isoforms (ER beta 1 and ER beta 2) in the response of MCF7 cells to antiestrogens and retinoids. The findings suggest that ER beta 1 may serve as a marker of responsiveness, while ER beta 2 may indicate resistance to antiestrogens, both alone and in combination with retinoids.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)